Overall rank by patents
#24,619
Across all tracked assignees
USPTO PatentsView assignee record - 11 granted patents across 4 technology areas, active 2015–2022. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: Y10T (TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION).
The verdict
Kapman holds 11 US patents across 4 technology areas, rank #24,619 of 50,000 tracked assignees.
Kapman AB has been granted 11 US utility patents between 2015 and 2022, placing Kapman AB at rank #24,619 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 3.5 claims per patent with primary concentration in Y10T (TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION). As a Foreign Corporation, Kapman AB is one of the more focused assignees in the PatentsView dataset. By volume, Kapman sits between KAGA Works Co., Ltd. (11 patents, rank #24,615) and KH Neochem Co., Ltd. (11 patents, rank #24,623) - the closest US assignees by grant volume. The composite Innovation Score of 19.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 3 grants, compared with 8 in the 2015–2019 window, a -62% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Kapman AB's 3.5 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while specialization in 4 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Kapman AB against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
KAGA WORKS CO., LTD.
11 patents
KANEFUSA KABUSHIKI KAISHA
11 patents
KANTAS PRODUCTS CO., LTD.
11 patents
KAOHSIUNG CHANG GUNG MEMORIAL HOSPITAL
11 patents
KBK Industries, LLC
11 patents
KBR WYLE SERVICES, LLC
11 patents
KEYCORE TECHNOLOGY CORP.
11 patents
KH NEOCHEM CO., LTD.
11 patents
KAPMAN AB
11 patents
What this shows Kapman holds 11 patents at rank #24,619, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Kapman's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
20 Top 94% higher than 6% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 5 | 45.5% |
| 2017 | 2 | 18.2% |
| 2019 | 1 | 9.1% |
| 2020 | 2 | 18.2% |
| 2022 | 1 | 9.1% |
Top 4 of 4 technology areas
Overall rank by patents
#24,619
Across all tracked assignees
19.9 out of 100
How to use this portfolio
Kapman's 11 grants land it in the top 94% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.